Clinical Trials Logo

Clinical Trial Summary

Objective: The primary objective in this study is to identify which (pheno)type of ALS patient has the most benefit from NIV in improving quality of life. Study population: Adult patients with ALS, PLS (Primary Lateral Sclerosis) of PSMA (Progressive Spinal Muscular Atrophy) in the Netherlands. Patients will be included during their first visit to one of the HMV centres in the Netherlands. Main study parameters/endpoints: The main study parameter is change in Quality of Life (QoL) defined as change in ALS Assessment Questionnaire (ALSAQ-40) in patients with ALS after initiation of NIV. Design: Multi-centre prospective cohort study consisting of 2 non-randomized cohorts, i.e. ALS patients who start NIV and ALS patients who do not start NIV at the time of inclusion in the present study. Duration: The total duration of the study: 3,5 years. Inclusion period: 30 months. Follow up time after initiation of NIV: 9 months. Thereafter, 6 months will be used for data analysis. Setting: Involvement of all (4) HMV centres in the Netherlands (Groningen, Maastricht, Rotterdam, Utrecht). Procedure: 250 ALS patients will be included. During the first regular visit to the HMV centre patients will be asked to participate in the study. Data will be recorded during regular visits to the HMV centre.


Clinical Trial Description

First visit: After informed consent the following data which are gathered as parts of usual care will be recorded in the case report form (CRF): - Pulmonary function: - FVC ( % predicted) upright and supine - capillary blood gas analysis, room air (pH, pCO2, HCO3-, pO2) - anamnestic questions (Borg scale 0-4) - Gender - Age - Percutaneous Endoscopic Gastrostomy (PEG)/ Percutaneous Radiological Gastrostomy (PRG) tube: yes/no - Medication - Weight/ BMI - Living situation - Civil status - The following clinical characteristics from their medical record (from neurologist or rehabilitation specialist): - Date of diagnosis - Type of ALS at onset - ALSFRS-R at the time of diagnosis - Pulmonary function at the time of diagnosis - Cognitive status (ECAS, ALS-FTD-Q) - Medical history - Validated questionnaires (online): - Quality of life questionnaires (SF 36, ALSAQ-40) - Respiratory insufficiency questionnaire (SRI) - ALS FRS R (patient version) - Bulbar symptoms questionnaire (CNS BFS) After the first visit patients will participate in one of the two cohorts (non-randomized): - Cohort 1: patients who start NIV in the first two months after the first visit to the HMV - Cohort 2: patients who do not start NIV in the first two months after the first visit to the HMV. Cohort 1: Data will be recorded at the moment of initiation of NIV and 3, 6 and 9 months after initiation. Data will be recorded during regular visits (to the HMV centre or at the patients home). - Pulmonary function: - capillary blood gas, room air (pH, pCO2 (kPa/ mmHg), HCO3- (mmol/l), SaO2 (%)) - anamnestic questions (Borg scale 0-4) - Nocturnal gas exchange by transcutaneous measurement, at the patients home - Mean tcpCO2 (kPa), Maximal tcpCO2 (kPa), mean oxygen saturation (%), lowest oxygen saturation (%) - Data from NIV equipment (compliance, modus, IPPA, EPAP, freq, mask type) - Use of NIV - hours a day/night - In case of no use: why not? - PEG/ PRG tube: yes/no - Survival - Tracheostomy or not - Weight - Validated online questionnaires: - Quality of life questionnaires (SF 36, ALSAQ-40) - Respiratory insufficiency questionnaire (SRI) - ALS FRS R (patient version) - Bulbar symptoms questionnaire (CNS BFS) - Nocturnal gas exchange, transcutaneous, at the patients home Cohort 2: Data will be recorded every 3 months until initiation of NIV or death or max 1,5 years after the first visit to the HMV. Data will be recorded during regular visits (to the HMV centre or at the patients home). - Pulmonary function: - Capillary blood gas (pH, pCO2 (kPa/ mmHg), HCO3- (mmol/l), SaO2 (%)) - anamnestic questions (Borg scale 0-4) - Nocturnal gas exchange by transcutaneous measurement, at the patients home - tcpCO2 (kPa), Maximal tcpCO2 (kPa), oxygen saturation (%), lowest oxygen saturation (%) - PEG/ PRG tube: yes/no - Survival - Tracheostomy or not - Weight - Cognitive status (from medical record) - Reason for not starting NIV - Validated online questionnaires: - Quality of life questionnaires (SF 36, ALSAQ-40) - Respiratory insufficiency questionnaire (SRI) - ALS FRS R (patient version) - Bulbar symptoms questionnaire (CNS BFS) - Nocturnal gas exchange, transcutaneous, at the patients home If a patient in cohort 2 will start with NIV, the patient will be transferred to cohort 1. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05033951
Study type Observational [Patient Registry]
Source University Medical Center Groningen
Contact Rineke Jaspers Focks, MD
Phone +31534875424
Email [email protected]
Status Not yet recruiting
Phase
Start date October 1, 2021
Completion date October 1, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04428775 - A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease Phase 2
Recruiting NCT04579666 - MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Recruiting NCT04082832 - CuATSM Compared With Placebo for Treatment of ALS/MND Phase 2/Phase 3
Completed NCT01925196 - Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
Completed NCT02496767 - Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year Phase 3
Recruiting NCT04494256 - A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB105 in Participants With Amyotrophic Lateral Sclerosis With or Without Poly-cytosine-adenine-guanine (CAG) Expansion in the Ataxin-2 Gene Phase 1
Completed NCT03706391 - Study of ALS Reversals 4: LifeTime Exposures
Recruiting NCT04882904 - Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part. N/A
Completed NCT04557410 - Open Label Study: Treatment of ALS Fatigue With PolyMVA Phase 1
Recruiting NCT05003921 - Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intrathecal Injection for ALS Phase 1
Not yet recruiting NCT04089696 - Validation of the "ExSpiron©" in Patients With ALS N/A
Not yet recruiting NCT04889898 - Remote Speech and Swallowing Assessment in ALS N/A
Recruiting NCT02917681 - Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis Phase 1/Phase 2
Active, not recruiting NCT03067857 - Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease Phase 1/Phase 2
Recruiting NCT02874209 - Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis N/A
Active, not recruiting NCT02567136 - Imaging Biomarkers in ALS
Completed NCT02059759 - Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2 Phase 2
Completed NCT02492516 - Intravenous Injection of Adipose Derived Mesenchymal Stem Cell for ALS Phase 1
Terminated NCT01999803 - A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS Phase 1
Completed NCT02405182 - MRI Biomarkers in ALS